Showing 1,661 - 1,680 results of 5,049 for search '"psoriasis"', query time: 0.12s Refine Results
  1. 1661
  2. 1662

    Prevalence of psoriatic arthritis in Chinese population with psoriasis: A multicenter study conducted by experienced rheumatologists by Hua Zhang, Miao Chen, Ran Cui, Xia Li, Kexiang Yan, Lihong Chen, Zhenghua Zhang, Ning Yu, Xinling Bi, Hui Deng, Yangfeng Ding, Qiong Huang, Sheng-Ming Dai, Lishao Guo

    Published 2023-06-01
    “…Reports on the prevalence of psoriatic arthritis (PsA) among Chinese patients with psoriasis are very limited. This study, conducted by rheumatologists, estimated the prevalence of PsA in a large number of Chinese patients with psoriasis. …”
    Get full text
    Article
  3. 1663
  4. 1664
  5. 1665
  6. 1666
  7. 1667
  8. 1668

    The Ameliorating Effect of Oral Paquinimod Administration against Imiquimod Induced Psoriasis-like Inflammation in Mice by Raghad Abdulsalam Khaleel, Munaf Hashim Zalzala

    Published 2023-06-01
    “…Psoriasis was induced in mice in this work using an imiquimod 5% cream, an immune response modifier that can cause psoriasis-like skin inflammation when given orally. …”
    Get full text
    Article
  9. 1669
  10. 1670

    A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy by N. S. Rudneva, E. V. Natarova, V. N. Sorotskaya, T. G. Sadunashvili

    Published 2021-12-01
    “…The use of adalimumab for 6 years in a patient suffering from psoriasis, psoriatic arthritis (PsA), vitiligo and autoimmune thyroiditis made it possible to control the activity of psoriasis and PsA, and also contributed to the regression of depigmentation foci. …”
    Get full text
    Article
  11. 1671
  12. 1672
  13. 1673
  14. 1674
  15. 1675
  16. 1676
  17. 1677

    Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials by Yuqian Wang, Sheng Li, Juan Bai, Xiaoxuan Cai, Shunli Tang, Peiyi Lin, Qingmiao Sun, Jianjun Qiao, Hong Fang

    Published 2023-04-01
    “…Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis. Objectives: This study aimed to assess the efficacy and safety of bimekizumab in treating patients with psoriasis and to determine the optimal maintenance dosing schedules of bimekizumab. …”
    Get full text
    Article
  18. 1678

    Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study by Nikolay N. Murashkin, Eduard T. Ambarchian, Roman V. Epishev, Alexander I. Materikin, Leonid A. Opryatin, Roman A. Ivanov, Daria S. Kukoleva, Marina Y. Pomazanova, Daria G. Kuptsova, Yana V. Kozyr, Andrey L. Bakulev

    Published 2020-12-01
    “…Background. The study of psoriasis biological therapy aspects in children has certain topicality due to the small number and disunity of individual observations and the lack of special registers for pediatric patients.Objective. …”
    Get full text
    Article
  19. 1679
  20. 1680